ArticleScience translational medicine2021
Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth.
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data.Journal of fungi (Basel, Switzerland) · 2026Review
- Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention.Advanced healthcare materials · 2026Article
- Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Optimizing genetic engineering approaches for protein loading into bacterial extracellular vesicles for vaginal drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Opportunities and barriers for innovation at the interface of engineering and maternal-fetal medicine.Communications engineering · 2026Article
- Preventing Preterm Birth: The Search for Tocolytic Synergism.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- The Application of Nano Drug Delivery Systems in Female Upper Genital Tract Disorders.Pharmaceutics · 2024Review
- Nanomedicine for Maternal and Fetal Health.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Hypotonic, gel-forming delivery system for vaginal drug administration.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Rethinking the application of nanoparticles in women's reproductive health and assisted reproduction.Nanomedicine (London, England) · 2024Review
- Regulation of 20α-Hydroxysteroid Dehydrogenase Expression in Term Pregnant Human Myometrium Ex Vivo.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- A comparison of neonatal outcomes after taking progesterone pills and progesterone intramuscular injections in preterm labor: An RCT.International journal of reproductive biomedicine · 2023Article
- Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions.Nanoscale advances · 2023Review
- MYB and ELF3 differentially modulate labor-inducing gene expression in myometrial cells.PloS one · 2023Article
- Cervicovaginal mucus barrier properties during pregnancy are impacted by the vaginal microbiome.Frontiers in cellular and infection microbiology · 2023Article
- In vitro and ex vivo models for evaluating vaginal drug delivery systems.Advanced drug delivery reviews · 2022Review
- Progesterone and its receptor signaling in cervical remodeling: Mechanisms of physiological actions and therapeutic implications.The Journal of steroid biochemistry and molecular biology · 2022Review
- Vaginal Nanoformulations for the Management of Preterm Birth.Pharmaceutics · 2022Review
- MPTHub: An Open-Source Software for Characterizing the Transport of Particles in Biorelevant Media.Nanomaterials (Basel, Switzerland) · 2022Article
- Association of maternal obesity with preterm birth phenotype and mediation effects of gestational diabetes mellitus and preeclampsia: a prospective cohort study.BMC pregnancy and childbirth · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
Inflammation contributes to nearly 4 million global premature births annually. Here, we used a mouse model of intrauterine inflammation to test clinically used formulations, as well as engineered nanoformulations, for the prevention of preterm birth (PTB). We observed that neither systemic 17a-hydroxyprogesterone caproate (Makena) nor vaginal progesterone gel (Crinone) was sufficient to prevent inflammation-induced PTB, consistent with recent clinical trial failures. However, we found that vaginal delivery of mucoinert nanosuspensions of histone deacetylase (HDAC) inhibitors, in some cases with the addition of progesterone, prevented PTB and resulted in delivery of live pups exhibiting neurotypical development. In human myometrial cells in vitro, the P4/HDAC inhibitor combination both inhibited cell contractility and promoted the anti-inflammatory action of P4 by increasing progesterone receptor B stability. Here, we demonstrate the use of vaginally delivered drugs to prevent intrauterine inflammation-induced PTB resulting in the birth of live offspring in a preclinical animal model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.